New Targets, New Combinations, New Treatment Goals: Assessing Therapeutic Options to Personalize Care in Multiple Myeloma

CME: 2.0

Target Audience

The target audience for this activity is hematologists and oncologists who treat patients with MM. Physicians, nurses, and other health care professionals interested in the treatment of MM are also invited to participate.

Activity Overview

Almost all patients with multiple myeloma (MM) eventually relapse with the disease course typically involving multiple relapses and remissions. Therapy selection for relapsed or refractory (R/R) MM is nuanced and affected by many variables. This along with the availability of novel therapies and accumulating evidence can make it difficult for clinicians to select appropriate therapy for individual patients. This accredited program discusses patient cases, applicable data, and management strategies in order to facilitate care for patients across the MM disease continuum.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Translate patient-specific factors, risk stratification, and treatment history into personalized treatment plans for patients with R/R MM
  • Assess recent results from pivotal trials on current and emerging therapeutic approaches for the treatment of R/R MM
  • Implement effective strategies to monitor and mitigate the negative impact of treatment-related toxicities in patients with R/R MM
  • Apply recent guidelines in parallel with practice-changing evidence on evolving single agent and combination approaches to real-world case scenarios typically encountered in R/R MM management

Post a comment to this article